Healthcare Industry News: FUZEON
News Release - April 10, 2007
Phase Bioscience Strengthens Management TeamDURHAM, N.C.--(HSMN NewsFeed)--Phase Bioscience, Inc. announced today the appointment of M. Nixon ("Nick") Ellis, M.B.A., Ph.D. as President and Chief Executive Officer and Member of the Board of Directors. Dr. Gabriel Cipau will take the position of Executive Chairman of the Board.
"Dr. Ellis is joining our rapidly maturing company at a critical juncture. His unique combination of experiences, including start-up management, fund raising and peptide therapeutic development and partnering will be instrumental in moving the company to the next level. The appointment of Nick will allow Phase Bioscience to expedite its drug development and delivery strategy, while simultaneously seeking additional funding," said Dr. Cipau commenting on the appointment.
Most recently, Dr. Ellis was President of Trimeris, Inc. where he was instrumental in the development of FUZEON, the first injectable peptide approved for the treatment of HIV disease. Before joining Trimeris, Dr. Ellis was a co-founder of Triangle Pharmaceuticals, Inc. where he served as President, Chief Operating Officer and as a Director. During his tenure at Triangle, Dr. Ellis played key roles in the licensing and development of Emtricitabine ( FTC ), in the company's Initial Public Offering and in establishing the company's alliance with Abbott Pharmaceuticals.
Dr. Ellis began his career at Burroughs Wellcome Co. as a virologist and held positions of increasing responsibility in the Division of Virology. After leaving his position as Assistant Division Director in Virology, he was named Assistant Director of the company's Business Development Group in London. Shortly before Glaxo's purchase of Wellcome, Dr. Ellis was appointed Global Brand Director of HIV in the Marketing Group. He received a B.S. from the University of South Carolina, an M.S. and Ph.D. in Microbiology from the University of Georgia and an M.B.A. from The University of North Carolina.
About Phase Bioscience
Phase Bioscience is focused on the development of biotherapeutics through innovative technology. By concentrating initially on medical markets with significant unmet need, such as certain forms of cancer, Phase Bioscience is developing a portfolio of products which deliver existing therapeutic agents with greater efficacy and lower side effects. Additionally, Phase Bioscience offers manufacturing services and processes, which provide for improved delivery and purification for therapeutic proteins and peptides. Phase Bioscience is a Research Triangle, North Carolina based company, currently in the process of raising venture capital Series B funding to further its purification and drug delivery technologies.
For more information, visit our website at www.phasebio.com.
Source: Phase Bioscience
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.